Actively Recruiting
Evaluating Safety and Effectiveness of Ultra-fraction Radiotherapy Before CAR-T Cell Therapy for Adults with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Led by Peking Union Medical College Hospital · Updated on 2026-03-24
20
Participants Needed
1
Research Sites
65 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of ultra-fraction radiotherapy combined with CAR-T cell therapy in patients with relapsed or refractory diffuse large B cell lymphoma DLBCL. This single-center, single-arm study focuses on patients who have not responded to at least two lines of chemotherapy and may have failed or are ineligible for stem cell transplantation. Participants receive ultra-fraction radiotherapy as a bridging treatment before the infusion of CD19 CAR-T cells. The study involves this combined treatment approach to assess its potential benefits and risks in managing DLBCL that has returned or not responded to previous therapies. During the study, participants will be monitored for treatment response at 3 and 6 months, as well as for progression-free survival, overall survival, duration of response, relapse rate, and severe side effects over a two-year period. Evaluations include assessing measurable disease, patient safety, and therapeutic effectiveness throughout follow-up visits lasting up to two years after treatment initiation.
CONDITIONS
Brief Title
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Research Team
J
Jing Ruan, Docter
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
